Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Radioimmunoassay’s (RIAs) are rapid, quantitative ways of measuring levels of antigen-specific antibody using a radioactively labelled substance. It is an in-vitro assay that measures the presence of an antigen with very high sensitivity. Basically, any biological substance for which a specific antibody exists can be measured, even in minute concentrations. RIA has many uses, including narcotics detection, blood bank screening for hepatitis virus, early cancer detection, measurement of growth hormone levels, tracking of leukaemia virus, diagnosis of peptic ulcers, and research with brain chemicals called neurotransmitters.
The global radioimmunoassay market is observing significant growth owing to surging usage of RIA in pharmaceutical industries, research labs, and contract research organizations (CROs). The market is further boosted by the need for quality and error-free results to ensure patient satisfaction in research labs and diagnostic centers. Furthermore, rising demand for high throughput and automated procedures would further provide significant growth opportunities to this market in the future. However, the market is hindered by high cost of the procedure and continuous innovations in various other immunoassay procedures such as ELISA.
The report analyses the global radioimmunoassay market based on product, application, end user and geography.
Based on product, the market is segmented into kits & reagents and analysers. Radioimmunoassay kits come in varied forms and types, and include a buffer solution for radioimmunoassay, a standard peptide in lyophilized powder form, an antibody in lyophilized powder which is specific to the antigen or peptide, a normal IgG serum, and an antibody IgG serum, along with a positive control for the test, and a separation technique of choice. The radioimmunoassay kits include, plates, tubes and reagents for different number of tests.
Based on application, this market is categorized into scientific research and clinical diagnosis. Radioimmunoassay are used for the clinical diagnosis of cancer, autoimmune diseases, infectious diseases, endocrine disorders and allergic diseases.
Various end users of this market are hospitals, academic research institute, clinical diagnostic laboratories and pharmaceutical industry & CRO. In the pharmaceutical industry RIA is used for drug testing. The market for RIA is expected to witness a noteworthy growth rate over the forecast period owing to rising use of radioimmunoassay techniques in cancer diagnosis and advancements in medical research.
By geography, the global radioimmunoassay market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and rest of the world. Europe accounted for the largest share in 2018, owing to advancements in medical research, clinical trials, growing geriatric population with cancer indication. Countries such as China and Japan are witnessing substantial growth in the radioimmunoassay market. Increasing activities for expansion is likely to boost the market in the future. In addition to this, Europe holds the second largest share in the radioimmunoassay market. Companies are investing more in R&D to find out applications of radioimmunoassay in the industry segments to increase their scope and demand.
The leading market players of the global radioimmunoassay market are Diasorin S.P.A., Euro Diagnostica AB, Merck Millipore Corporation, Diasource Immunossays S.A, Stratec Biomedicals AG, Berthold Technologies Gmbh & Co. Kg, Izotop, Beckman Coulter, Inc., Cisbio, MP Biomedicals LLC, Perkinelmer, Inc., IBL International (Tecan Company) and DRG International, Inc. In July 2018, ZenTech signed a strategic agreement to transfer its portfolio of radioimmunoassays (RIA) to DIAsource ImmunoAssays, a BioVendor group company. ZenTech has strategically reoriented itself to focus on newborn screening and early life stage diseases.
The global radioimmunoassay market is segmented based on product, application, end user and geography. Based on product, the market is segmented into kits & reagents and analysers. Radioimmunoassay kits come in varied forms and types, and include a buffer solution for radioimmunoassay, a standard peptide in lyophilized powder form, an antibody in lyophilized powder which is specific to the antigen or peptide, a normal IgG serum, and an antibody IgG serum, along with a positive control for the test, and a separation technique of choice.
Based on application, this market is categorized into scientific research and clinical diagnosis. Radioimmunoassay are used for the clinical diagnosis of cancer, autoimmune diseases, infectious diseases, endocrine disorders and allergic diseases.
Various end users of this market are hospitals, academic research institute, clinical diagnostic laboratories and pharmaceutical industry & CRO. In the pharmaceutical industry RIA is used for drug testing.
By geography, the global radioimmunoassay market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and rest of the world. Europe accounted for the largest share in 2018, owing to advancements in medical research, clinical trials, growing geriatric population with cancer indication. Countries such as China and Japan are witnessing substantial growth in the radioimmunoassay market. Increasing activities for expansion is likely to boost the market in the future.
Why to buy this report:
